SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): MARCH 14, 2000
--------------
CELSION CORPORATION
(Exact name of registrant as specified in its charter)
MARYLAND 000-14242 52-1256615
- --------------------------------------------- ----------------------- ----------------------
(State or other jurisdiction of incorporation) (Commission file number) (I.R.S. Employer
Identification Number)
10220-I OLD COLUMBIA ROAD COLUMBIA, MARYLAND 21046-1705
-------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (410) 290-5390
--------------
ITEM 5. OTHER EVENTS.
As previously reported, on February 7, 2000, the Company issued a call
for redemption, at the prescribed redemption price of $.01 per underlying share,
of its outstanding Series 700 and Series 800 Warrants, which enable the holders
thereof to purchase shares of Common Stock at prices of $1.00 per share and
$0.90 per share, respectively. The date set for redemption was March 10, 2000.
In response to the redemption call, the Company received notices of (i)
the exercise of Series 700 Warrants for the purchase of a total of 2,630,000
shares of Common Stock and (ii) the exercise of Series 800 Warrants for the
purchase of a total of 2,650,000 shares of Common Stock, representing all
previously outstanding Series 700 and 800 Warrants. As a result of such
purchases, the Company has received aggregate proceeds of $5,015,000. All shares
being issued to the holders of such warrants are restricted and not registered,
are endorsed with a restrictive legend, and are subject to "stop transfer"
notations recorded with the Company's transfer agent.
The Company believes that the proceeds from the exercise of the
warrants, together with the net proceeds received from the closing of its
private placement offering on January 31, 2000, will be sufficient to fund the
completion of Phase I and Phase II clinical trials as currently contemplated for
its breast cancer treatment system and its benign prostatic hyperplasia
treatment system and to enable the Company to undertake further development of
the heat-sensitive liposome technology previously licensed from Duke University.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: March 14, 2000
CELSION CORPORATION
-----------------------------------------
(Registrant)
By: /s/ John Mon
-----------------------------------------
John Mon
Treasurer, Secretary and General Manager
-2-